Payment overview · 2025
General Payments
$58,090.44
350 reported records · 35 companies
Healthcare provider profile · identity verified
Timothy Wayne Prestley, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · TUSCALOOSA, AL · NPI 1548421803
Verified facts
What the public records show
CMS Open Payments records show Timothy Wayne Prestley, M.D. received $58,090.44 in general payments during 2025 across 350 reported records.
ABBVIE INC. accounted for 75.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 43 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Briviact, Epidiolex, Qulipta, Trintellix, Ubrelvy, Xeomin.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Ubrelvy by this doctor in 2024.
ARGENX US, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VYVGART as an associated drug or biological on 6851 records involving 2825 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vyvgart by this doctor in 2024.
Alexion Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIRIS as an associated drug or biological on 303 records involving 233 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Soliris by this doctor in 2024.
JAZZ PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EPIDIOLEX as an associated drug or biological on 10990 records involving 3626 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Epidiolex by this doctor in 2024.
Merz Pharmaceuticals, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xeomin as an associated drug or biological on 8663 records involving 4073 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Xeomin by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Xcopri by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAGARD LIQUID as an associated drug or biological on 29 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Gammagard Liquid by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trintellix by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $43,761.18 | 75.3% | 79 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $9,338.10 | 16.1% | 41 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $608.26 | 1.1% | 25 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $334.08 | 0.6% | 19 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $272.04 | 0.5% | 9 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $248.01 | 0.4% | 11 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $244.36 | 0.4% | 11 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$223.64 | 0.4% | 10 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $221.08 | 0.4% | 6 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $218.12 | 0.4% | 11 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $213.09 | 0.4% | 8 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $209.36 | 0.4% | 11 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $207.51 | 0.4% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $200.98 | 0.3% | 14 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $182.06 | 0.3% | 8 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $168.90 | 0.3% | 7 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $152.49 | 0.3% | 8 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$146.97 | 0.2% | 8 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $142.89 | 0.2% | 7 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $112.69 | 0.2% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $101.64 | 0.2% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $99.76 | 0.2% | 6 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $84.32 | 0.1% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $81.67 | 0.1% | 4 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $79.88 | 0.1% | 4 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $70.58 | 0.1% | 3 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $64.21 | 0.1% | 3 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $55.60 | 0.1% | 3 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $53.95 | 0.1% | 2 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $43.67 | 0.1% | 2 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $38.48 | 0.1% | 2 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $38.28 | 0.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.70 | 0.1% | 2 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $24.73 | 0.0% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $16.16 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $49,668.75 | 18 |
| Food and Beverage | $6,344.59 | 323 |
| Consulting Fee | $1,525.00 | 1 |
| Travel and Lodging | $463.40 | 6 |
| Education | $88.70 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $21,278.41 | 31 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18,330.62 | 26 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $10,375.90 | 18 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $9,338.10 | 41 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $436.44 | 36 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $431.29 | 18 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $334.08 | 19 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $314.94 | 14 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $272.04 | 9 | 2025 |
Source payment records
|
|||||
| AMPYRA Normalized: ampyra |
Drug | Merz Pharmaceuticals, LLC | $244.14 | 8 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $244.14 | 8 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $225.36 | 10 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $213.09 | 8 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $207.51 | 7 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $200.98 | 14 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. | $199.09 | 10 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $176.97 | 7 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $168.90 | 7 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $168.39 | 7 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $161.03 | 7 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $152.49 | 8 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $146.97 | 8 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $142.89 | 7 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $124.49 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $112.69 | 6 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $93.63 | 5 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $84.32 | 4 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $81.34 | 7 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $79.88 | 4 | 2025 |
Source payment records
|
|||||
| EMGALITY Normalized: emgality |
Drug | Lilly USA, LLC | $56.32 | 3 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $55.60 | 3 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $53.95 | 2 | 2025 |
Source payment records
|
|||||
| REJOYN Normalized: rejoyn |
Device | Otsuka Pharmaceutical Development & Commercialization, Inc. | $46.38 | 2 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $45.10 | 2 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $43.67 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $43.44 | 3 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $38.48 | 2 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $38.28 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $36.57 | 2 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $31.70 | 2 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | Octapharma USA, Inc. | $24.73 | 1 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $21.03 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $16.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 86 | exact normalized | Medicare Part D |
| Briviact briviact |
2025 | Briviact | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| EPIDIOLEX epidiolex |
2025 | Epidiolex | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 35 | exact normalized | Medicare Part D |
| Xeomin xeomin |
2025 | Xeomin | 2024 | 32 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
86 | 34 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
35 | 12 |
| ARGENX US, INC. Exact reporting entity; no affiliate inference |
2025 | VYVGART open payments reported associated product |
CMS Open Payments — General Payments 6851 supporting records · 2825 recipient NPIs · example record 1240416066 |
Vyvgart · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Alexion Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SOLIRIS open payments reported associated product |
CMS Open Payments — General Payments 303 supporting records · 233 recipient NPIs · example record 1202913090 |
Soliris · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| JAZZ PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | EPIDIOLEX open payments reported associated product |
CMS Open Payments — General Payments 10990 supporting records · 3626 recipient NPIs · example record 1234297758 |
Epidiolex · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Merz Pharmaceuticals, LLC Exact reporting entity; no affiliate inference |
2025 | Xeomin open payments reported associated product |
CMS Open Payments — General Payments 8663 supporting records · 4073 recipient NPIs · example record 1232555385 |
Xeomin · 2024 Exact normalized brand match · 1 Part D row |
32 | 13 |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAGARD LIQUID open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 8 recipient NPIs · example record 1223786557 |
Gammagard Liquid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 321 | 67 |
| Tizanidine Hcl | Tizanidine Hcl | 147 | 55 |
| Lacosamide | Lacosamide | 121 | 23 |
| Botox | Onabotulinumtoxina | 86 | 34 |
| Donepezil Hcl | Donepezil Hcl | 66 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 60 | 18 |
| Xcopri | Cenobamate | 59 | suppressed |
| Alprazolam | Alprazolam | 56 | 20 |
| Clonazepam | Clonazepam | 53 | 12 |
| Qulipta | Atogepant | 46 | suppressed |
| Bupropion Xl | Bupropion Hcl | 43 | 13 |
| Memantine Hcl | Memantine Hcl | 43 | 17 |
| Ubrelvy | Ubrogepant | 35 | 12 |
| Xeomin | Incobotulinumtoxina | 32 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | suppressed |
| Methocarbamol | Methocarbamol | 29 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 25 | 13 |
| Soliris | Eculizumab | 24 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 23 | 12 |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 22 | suppressed |
| Briviact | Brivaracetam | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Epidiolex | Cannabidiol (Cbd) | 20 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 16 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 14 | suppressed |
| Gralise | Gabapentin | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Vimpat | Lacosamide | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 13 | suppressed |
| Gammaplex | Immun Glob G(Igg)/Gly/Iga 0-50 | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Vyvgart | Efgartigimod Alfa-Fcab | 13 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Kesimpta Pen | Ofatumumab | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $58,090.44 · 350 records | ABBVIE INC. | AMPYRA, AUSTEDO XR, Auvelity, BOTOX, Briviact, CAPLYTA, CREXONT, Dyanavel XR, EMGALITY, EPIDIOLEX, FANAPT, FYCOMPA, HYQVIA, Hizentra, INBRIJA, INGREZZA, KESIMPTA, KISUNLA, LEQEMBI, NUPLAZID, NURTEC ODT, Ocrevus Zunovo, PANZYGA, PONVORY, QULIPTA, REJOYN, REXULTI, Rystiggo, SPRAVATO, Sunosi, TRINTELLIX, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VRAYLAR, VYALEV, VYEPTI, WAINUA, WAKIX, Xeomin, ZAVZPRET, ZTLido | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error